Adverse Drug Event
Conditions
Keywords
Adverse Drug Event, Choosing Wisely Canada, Deprescribing, Elderly, Frailty, High value healthcare, Medication rationalization, Medication stewardship, Polypharmacy
Brief summary
Reducing medications and associated side effects in older adults: an electronic hospital-based intervention
Detailed description
Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada and up to 20% of return visits to the hospital within 30 days of discharge. Many ADEs are preventable or ameliorable through interventions to reduce inappropriate prescribing. MedSafer, the intervention software, applies an electronic set of criteria, previously designed and piloted on one thousand (1000) hospitalized patients by a group of Quebec and Ontario internists, geriatricians, palliative care doctors and pharmacists, to identify potentially inappropriate medications (PIMs) in the hospitalized elderly and generate instructions for the patient and physician for safe discontinuation. The current study seeks to partially automate the deprescribing process and to demonstrate the efficacy of this type of intervention on adverse drug events at 30-days post hospital discharge. At the time of hospitalization, the patient's medications, co-morbidities, and a measure of frailty will be entered into the MedSafer software which will output an individualized and prioritized deprescription plan for the most responsible physician's consideration. Any subsequent medication changes will be transmitted to relevant community physicians. The study will evaluate the impact of stopping PIMs on the occurrence of ADEs within 30 days of discharge, as compared to usual care. This study will take place on the clinical teaching units (CTUs) at 11 hospitals from seven university hospital centres across Canada. Based on historical data, the investigators estimate a combined 5200 eligible patients per year with nearly 50% taking ten or more medications. Many will have multiple medical co-morbidities such as diabetes, heart disease, and renal insufficiency. A large portion will meet criteria for geriatric syndromes such as frailty and will be at high risk for the development of delirium, falls and functional decline. This population is ideal for a generalizable deprescribing study. All patients aged 65 or older who meet inclusion/exclusion criteria will be enrolled. A trained research assistant will identify eligible patients and medications will be screened using MedSafer. A deprescribing plan will be generated for the CTU team containing the rationale for suggested medication changes and strategies for safe and successful deprescription. The CTU team will then decide, in conjunction with the patient/proxy and relevant consultants, whether to apply the suggested modifications.
Interventions
OTHERDeprescribing opportunities
An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
Sponsors
Canadian Institutes of Health Research (CIHR)
University Health Network, Toronto
The Ottawa Hospital
Foothills Medical Centre
University of Alberta
Kingston Health Sciences Centre
University of British Columbia
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Masking description
Medical chart abstracts compiled at discharge (including any subsequent visits within 30 days) will be combined with the patient telephone interview into a case summary report which will be reviewed independently by two trained and blinded clinician reviewers who will be made up of pharmacists and physicians from each study site (but who will not adjudicate any patients from their own site).
Intervention model description
The duration of the project will be a total of (approx.) 96 weeks. This is a stepped wedge cluster randomized trial study design (see PDF attachment entitled MedSafer, Figure 1 - note start date will be August 2017 not July 2016). The intervention component will be administered sequentially to six (6) clusters (by city). A randomly selected single cluster will move from control data collection to intervention data collection every 200 patients or roughly every 12 weeks (96 total weeks), which will be followed by 12 weeks to complete follow up and another 36 to analyze data. Please see PDF attachment entitled MedSafer, Figure 2 which refers to both parts of the study (quality improvement and follow up components). It describes the follow up component of the study (a 30-day telephone follow-up to ascertain adverse drug events- please note the gray-shaded boxes refer to the Quality Improvement Project-Part 1).
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients aged 65 years and older * patients who take five or more medications in the community * patients who are cognitively impaired or otherwise unable to provide consent will still be included as this subpopulation of patients may be at greatest risk of ADEs because of their communication problems.
Exclusion criteria
* patients who take four or fewer medications in the community * patients expected to die within 30 days or be transferred to a palliative care unit/another hospital * patients without provincial health insurance or who normally live outside that province * patients previously enrolled * inability for patient or proxy to speak English or French * no means of contacting patient or proxy post-discharge Patients discharged from non-study units will be excluded unless that unit is a transitional care, rehabilitation, or post-acute care unit which bridges the gap between acute medical hospitalization and community services.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Drug Events within 30 days post-discharge (ascertained via telephone interviewer and adjudicated via clinician reviewers) | Interview performed 30-35 days post-discharge. | Post-discharge telephone interview performed by trained personnel using a modification of the Australian two-step adverse reaction and drug event report. Two trained and blinded clinician reviewers will independently use the Leape and Bates approach to assess whether an ADE was present (yes/no) and if so what was the nature of the injury resulting from it using a four-point Likert scale (definitely preventable, probably preventable, probably not preventable, and definitely not preventable), and assess the probability that an event was attributable to a specific drug that was newly started, changed or continued during hospitalization. In cases of disagreement, a third trained and blinded clinician will review and determine the final assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality within 30-days post discharge | 30-days post hospital discharge | Death following hospital discharge |
| Proportion of participants with one or more potentially inappropriate medications deprescribed | At hospital discharge | Proportion of participants with one or more potentially inappropriate medications deprescribed at discharge between intervention and control |
| Quality of sleep | 30 days post hospital discharge | Quality of sleep measured by the PROMIS Sleep Disturbance 4a measured pre- and post-hospitalization compared between intervention and control |
| Adverse events | 30 days post hospital discharge | The proportion of patients who had one or more adverse events (falls, hospitalization, death, unplanned encounter with the healthcare system |
| Falls post hospital discharge | 30 days post hospital | The proportion of patients with one or more self-reported falls post hospital discharge |
| Quality of life of participants | At 30-days post hospital discharge | Quality of life as measured by EQ5D-5L and reported based on reported Canadian time trade-off values (from 0-1 with higher equal to better quality of life) |
| Number of potentially inappropriate medications | At hospital discharge and at 30-days post hospital discharge | The absolute number of potentially inappropriate medications at discharge among patients who were identified as having a potentially inappropriate medication at admission and for who a deprescribing opportunity was generated and presented to the treating team |
Other
| Measure | Time frame | Description |
|---|---|---|
| Total number of medications at 30-days | At 30-days post discharge | Total number of mediations at 30 days (reported as median and interquartile range) compared between intervention and control |
| Sensitivity analysis for adverse drug events | At 30-days post hospital discharge | Proportion of participants with 1 or more adverse drug events as defined by 4 or more on the 6-point Leape and Bates Likert scale |
| Proportion of potentially inappropriate medications that remained stopped | 30-days post hospital discharge | Proportion of potentially inappropriate medications that remained stopped between intervention and control |
| Unplanned visits with the healthcare system | 30-days post hospital discharge | Proportion of patients with any self-reported unplanned visit with the healthcare system compared between intervention and control (emergency room visits and hospitalizations) |
| Death post hospital discharge | 30-days post hospital discharge | Proportion of patients who died post-hospital discharge compared between the intervention and control groups |
Countries
Canada
Outcome results
None listed